Sign in

CIK 0001799788 · Non-accelerated filer<br>Smaller reporting company

Greenwich LifeSciences, Inc.

Sign in to watch
Ticker
GLSI
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
205473709
Phone
203-434-3290
Business address
3992 BLUEBONNET DR, BUILDING 14, STAFFORD, TX, 77477
  1. 4 Open-market buy CEO and CFO bought 2,000 shares at $19.35 ($38,700)
  2. 4 Open-market buy VP Clinical Reg Affairs bought 250 shares at $19.20 ($4,800)
  3. 4 Open-market buy CEO and CFO bought 1,500 shares at $17.37 ($26,055)
  4. 4 Open-market buy VP Clinical Reg Affairs bought 250 shares at $16.50 ($4,125)
  5. 4 Open-market buy CEO and CFO bought 1,500 shares at $15.18 ($22,770)
  6. 4 Open-market buy CEO and CFO bought 4,000 shares at $15.19 ($60,760)
  7. 4 Open-market buy CEO and CFO bought 1,000 shares at $13.01 ($13,010)
  8. 4 Open-market buy VP Clinical Reg Affairs bought 250 shares at $12.94 ($3,235)
  9. 4 Open-market buy CEO and CFO bought 2,000 shares at $13.11 ($26,220)
  10. 8-K Event Shareholder vote results
  11. 4 Open-market buy CEO and CFO bought 1,000 shares at $13.84 ($13,840)
  12. 4 Open-market buy VP Clinical Reg Affairs bought 250 shares at $13.98 ($3,495)
  13. 10-Q Report Quarterly Report
  14. 4 Open-market buy CEO and CFO bought 2,000 shares at $8.79 ($17,580)
  15. DEFA14A Proxy Proxy Materials
  16. DEF 14A Proxy Proxy Statement
  17. 4 Open-market buy CEO and CFO bought 3,000 shares at $9.75 ($29,250)
  18. 4 Open-market buy CEO and CFO bought 2,000 shares at $9.72 ($19,440)
  19. 4 Open-market buy CEO and CFO bought 1,000 shares at $9.46 ($9,460)
  20. 4 Open-market buy CEO and CFO bought 1,000 shares at $9.23 ($9,230)

Page 7 of 14 · 279 filings